US · GRFS
Grifols, S.A.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Barcelona 08174
- Website
- grifols.com
Price · as of 2024-12-31
$8.23
Market cap 7.7B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.90 | +299.76% |
| Intrinsic Value(DCF) | $3.32 | -59.66% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $4.60 | -44.11% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $1.80 | $5.00 | |||
| 2011 | $5.63 | $43.00 | $42.56 | $0.00 | $7.70 |
| 2012 | $12.08 | $40.33 | $107.28 | $2.20 | $22.80 |
| 2013 | $18.00 | $37.42 | $78.39 | $1.70 | $7.40 |
| 2014 | $13.90 | $37.74 | $47.59 | $0.00 | $23.70 |
| 2015 | $13.40 | $35.64 | $20.08 | $0.00 | $22.30 |
| 2016 | $15.64 | $33.25 | $0.00 | $0.00 | $10.30 |
| 2017 | $19.62 | $36.28 | $0.95 | $0.00 | $16.40 |
| 2018 | $18.05 | $34.92 | $1.76 | $0.00 | $12.20 |
| 2019 | $20.88 | $35.19 | $1.68 | $0.00 | $23.40 |
| 2020 | $15.40 | $32.48 | $0.05 | $2.00 | $13.40 |
| 2021 | $10.93 | $26.37 | $3.42 | $0.00 | $0.30 |
| 2022 | $7.51 | $27.32 | $0.00 | $0.00 | $9.60 |
| 2023 | $6.89 | $48.13 | $0.00 | $0.00 | $1.20 |
| 2024 | $8.29 | $28.12 | $1.88 | $0.00 | $4.60 |
AI valuation
Our deep-learning model estimates Grifols, S.A.'s (GRFS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.90
- Current price
- $8.23
- AI upside
- +299.76%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.32
-59.66% upside
Graham-Dodd
—
— upside
Graham Formula
$4.60
-44.11% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GRFS | Grifols, S.A. | $8.23 | 7.7B | +242% | -60% | — | -44% | 10.85 | 0.82 | 0.67 | 9.37 | 6.98 | -1.08 | 38.75% | 16.53% | 2.18% | 7.89% | 3.72% | 2.09% | 1.71 | 1.54 | 2.66 | 0.96 | 6.13 | 15556.00% | 941.00% | -67929.00% | 11.02% | 0.42 | 3.46% | 0.02% | 0.20% | 28.68% | 11.66 | 26.19 | 1.93 | 0.96 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| AVTR | Avantor, Inc. | $9.05 | 6.17B | +191% | -61% | — | — | -11.27 | 1.07 | 0.91 | 68.88 | — | -2.28 | 32.65% | -3.76% | -8.09% | -9.20% | -2.61% | -4.44% | 0.71 | -1.45 | 1.78 | 1.04 | 25.82 | -17500.00% | -341.00% | -2847.00% | 8.29% | 0.45 | 5.24% | 0.00% | 0.00% | 4.92% | -38.81 | 19.30 | 1.46 | 1.37 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| CORT | Corcept Therapeutics Inco… | $35.70 | 3.8B | +198% | +64% | -69% | -45% | 38.06 | 5.77 | 4.91 | 49.30 | — | 5.77 | 98.30% | 5.88% | 13.09% | 14.79% | 15.32% | 11.71% | 0.01 | — | 2.92 | 2.60 | -1.67 | -3333.00% | 1279.00% | -2762.00% | 3.80% | 0.85 | 48.48% | 0.00% | 0.00% | 6.58% | 75.23 | 23.77 | 4.43 | 14.49 |
| DVA | DaVita Inc. | $156.30 | 10.45B | -3% | -61% | — | -21% | 12.29 | -20.36 | 0.97 | 10.42 | — | -1.57 | 27.00% | 14.74% | 5.47% | -407.09% | 12.61% | 6.21% | -23.12 | 3.66 | 1.29 | 1.19 | 5.41 | -1137.00% | 646.00% | -1063.00% | 9.89% | 0.60 | 10.50% | 0.00% | 0.00% | 13.52% | 13.69 | 21.00 | 2.02 | 1.68 |
| GMED | Globus Medical, Inc. | $95.46 | 12.89B | +11% | +76% | -55% | 0% | 23.57 | 2.77 | 4.31 | 16.77 | 5.58 | 5.30 | 67.41% | 16.33% | 18.30% | 12.29% | 10.63% | 10.19% | 0.03 | — | 4.26 | 2.48 | -0.56 | 42267.00% | 1665.00% | 4530.00% | 4.64% | 1.51 | 14.79% | 0.00% | 0.00% | 3.63% | 25.51 | 20.79 | 4.16 | 12.01 |
| HALO | Halozyme Therapeutics, In… | $69.53 | 8.21B | +26% | +70% | -87% | +68% | 26.42 | 171.48 | 5.99 | 9.10 | — | -5.53 | 78.13% | 58.45% | 22.69% | 153.59% | 93.94% | 13.81% | 0.00 | 45.03 | 4.66 | 3.30 | -0.15 | -2536.00% | 3755.00% | 3762.00% | 7.70% | 3.68 | 109.29% | 0.00% | 0.00% | 22.29% | 10.08 | 12.76 | 5.89 | 3.99 |
| HSIC | Henry Schein, Inc. | $82.39 | 9.99B | +2% | -60% | -90% | -52% | 24.70 | 3.03 | 0.75 | 13.28 | 342.43 | -4.95 | 29.14% | 5.75% | 3.02% | 11.99% | 9.02% | 3.71% | 1.14 | 5.05 | 1.38 | 0.56 | 3.51 | 721.00% | 403.00% | -1331.00% | 5.83% | 0.22 | 8.87% | 0.00% | 0.00% | 8.65% | 17.63 | 23.32 | 1.01 | 2.86 |
| MASI | Masimo Corporation | $175.35 | 9.42B | — | -60% | — | -71% | -62.06 | 13.04 | 6.16 | 31.37 | — | 16.55 | 61.90% | 20.30% | -9.92% | — | — | — | 0.72 | — | 2.49 | 1.40 | 1.17 | — | — | — | 2.10% | 0.58 | — | 0.00% | 0.00% | 3.87% | 31.51 | 49.38 | 6.40 | 8.77 |
| MOH | Molina Healthcare, Inc. | $154.05 | 7.93B | +43% | +423% | -46% | +17% | 16.40 | 1.90 | 0.17 | 7.63 | — | 4.13 | 8.97% | 1.72% | 1.04% | 11.02% | 52.20% | 3.03% | 0.97 | 4.07 | 1.69 | 1.06 | -0.31 | -5632.00% | 1175.00% | -21691.00% | -8.21% | -0.07 | -53.04% | 0.00% | 0.00% | 12.92% | 9.53 | -11.70 | 0.16 | 4.20 |
About Grifols, S.A.
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
- CEO
- Jose Ignacio Abia Buenache
- Employees
- 23.83K
- Beta
- 1.21
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.32 ÷ $8.23) − 1 = -59.66% (DCF, example).